Tucatinib improves progression-free survival in metastatic, HER2-positive breast cancer
Addition of tucatinib to trastuzumab emtansine (T-DM1) extended progression-free survival (PFS) among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, according to results from the HER2CLIMB-02 trial. HER2-positive breast cancer has a predilection to spread to the brain, and when this occurs, prognosis is poor. A previous phase 2 trial, HER2CLIMB (NCT02614794), found that the addition of tucatinib…
No radiotherapy after breast-conserving surgery is safe in selected younger patients
Avoiding radiotherapy after breast-conserving surgery in selected younger (50–69) post-menopausal patients appears not to increase risk of recurrence nor to decrease survival, as is suggested by results of the single-arm IDEA trial. Radiotherapy is recommended after lumpectomy to improve local control of invasive breast cancer and a modest survival benefit. However, the absolute benefit of radiotherapy is not the same…
Fast menstrual resumption after interruption of endocrine therapy
Women who interrupt endocrine therapy to become pregnant almost all recover menses within 6 months. Younger age is associated with a shorter time to and a higher chance of pregnancy, as was shown by results of the POSITIVE trial. The primary outcomes of the POSITIVE trial (NCT02308085) showed that, in women with previous HR-positive early breast cancer, temporary interruption of…
Olaparib maintenance has favourable safety profile in triple-negative breast cancer
In patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), maintenance olaparib/pembrolizumab shows similar efficacy outcomes compared with chemotherapy/pembrolizumab but with a more favourable safety profile, the results from KEYLYNK-009 demonstrated. Patients with previously untreated, locally recurrent inoperable or metastatic TNBC can benefit from treatment with pembrolizumab (plus chemotherapy), as results from the phase 3 KEYNOTE-355…
Exercise program improves quality of life for patients with metastatic breast cancer
Patients with metastatic breast cancer who took part in a 9-month structured exercise program reported less fatigue and an improved quality of life compared with those who did not undergo the exercise program, according to results from the PREFERABLE-EFFECT trial. Breast cancer and its treatments can cause side effects such as fatigue, nausea, pain, and shortness of breath, which can…
Highest benefit of neoadjuvant nivolumab in breast tumours with high PD-L1 expression and/or low oestrogen receptor expression
The benefit of neoadjuvant nivolumab is highest in patients with high PD-L1 expression and low oestrogen receptor (ER) expression, according to the results of an exploratory biomarker analysis of CheckMate 7FL. Recently, results from the phase 3 CheckMate 7FL trial (NCT04109066) showed a benefit of the addition of nivolumab to neoadjuvant chemotherapy and adjuvant endocrine therapy in patients with newly…
Letter from the Editor
Dear esteemed readers,It is with great pleasure and pride that I present the Congress Report on UEG Week 2023, held from October 14 to October 17. This year’s event saw an unprecedented level of international engagement, with a staggering 11,200 individuals from over 120 countries participating. The enthusiasm and dedication of the global medical community were truly commendable, showcasing the…
DIVERSITY1: Filgotinib results in Crohn’s disease leave investigators puzzled
Although filgotinib did not achieve its primary endpoints in the induction part of a phase 3 trial in Crohn’s disease (CD), it successfully met its efficacy endpoints in the maintenance part of the study. The preferential JAK1 inhibitor filgotinib was assessed in participants with moderately to severely active CD in the double-blind, randomised, placebo-controlled, phase 3 DIVERSITY1 study (NCT02914561). The…
SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD
Risankizumab outperformed ustekinumab in achieving endoscopic remission in participants with Crohn’s disease (CD). Moreover, risankizumab was superior to ustekinumab for all secondary efficacy endpoints. The safety profiles of the 2 agents were similar, albeit participants on ustekinumab had a numerically higher rate of serious adverse events (AEs).The phase 3, head-to-head SEQUENCE trial (NCT04524611) compared the efficacy and safety of the…
Guselkumab provides benefits in UC regardless of advanced therapy history
Induction therapy with guselkumab was efficacious in participants with moderately to severely active ulcerative colitis (UC), irrespective of treatment history with advanced therapies. The phase 3 QUASAR trial results demonstrated the benefits of guselkumab over placebo across clinical, symptomatic, and endoscopic endpoints.“The IL-23 inhibitor guselkumab has been approved for the treatment of plaque psoriasis and psoriatic arthritis,” said Prof. Axel…
Posted on
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy